

Board Meeting in Public Tuesday, 30 September 2025

Title of Report	NHSBT Financial Performance Report		Agenda No.	3.3				
Nature of Report	⊠ Official	☐ Official Sensitive						
Author(s)	Mark Taylor – Assistant Finance Director Hannah Wigley – Senior Corporate Financial Planning Manager							
Lead Executive	Carl Vincent – Chief Financial Officer							
Non-Executive Director Sponsor	Ian Murphy							
Presenter(s) at Meeting	Mark Taylor – Assistant Finance Director							
Presented for	☐ Approval ☐ Information							
	☐ Update							
Purpose of the report and key issues								
The budget for 2025-26 reflects a planned deficit of £12.8m driven through non-recurrent expenditure (Transformation), approved at the April Board. The financial plan is aligned to business plan priorities, and the sustainable position is fully funded versus expected volumes and activity. The latest forecast reports an improved position for the year , a deficit of £9.3m (£3.5m ahead of plan). All divisions reporting in line or better than plan. That said, a small number of issues remain for 2025-26 that require mitigation. These are primarily driven by the need for additional Donor Experience (DEX) resource, to ensure a smooth exit from the amber alert, which finished late July. To support strategies aimed at improving appointment booking rates , the Executive Team has approved a non-recurrent full-year budget overrun of £1.7m. This will be funded through the release of £1.5m from the contingency earmarked for DEX within the budget build process. The remaining £0.2m will be covered through other NHSBT underspends. It is also important to acknowledge the progress made since quarter 1. A number of previously identified finance issues in Organ Donation, Clinical Services and Tissues and Eye Services have now been fully mitigated for 2025–26 and have therefore been removed from the current issues table. Overall, we continue to present a position which suggests we can work within our financial envelope, and we will continue to pay close attention to any non-recurrent mitigations which will need to be addressed through the 2026-27 planning process								
Previously Considered by								
Included in the ET papers for the 16/09/2025 meeting.								



Blood and Transplant

					4 .	
· •	\sim	mn	กกท	~	241	n
- IN F	=(.()		nen	11.14	711	w

- i. Note; the ET have approved a £1.7m cost overrun in DEX to support and maintain the smooth exit out of amber alert.
- ii. Note; the latest forecast continues to align with the formal Q1 forecast, which confirms a fully sustainable position for 2025-26, where we are likely to deliver this year within our financial envelope (slide 3).
- iii. Note; proposals to strengthen cost control have been factored into this report. (Slide 4) provides an update on cost overruns as we know them.
- iv. Note; Capital plan fully utilises this year's allocation £25m and includes an element of over programming to mitigate potential slippage. (slide 7)
- v. Note; Cost improvement plan continues to carry some risk to delivery, and this is subject to ongoing review work to mitigate (slide 8).

Risk(s) identified (Link to Board Assurance Framework Risks)

BAF-05 The proposals set out in the paper aim to balance financial resilience, the need to deliver resilient services, and external expectations of price increases. If we are unable to secure sufficient increases in funding there is a risk that we overspend and further undermine our long term financial resilience, or that we decide to cut costs in a way that undermines our ability to meet expectations of the volume and quality of our services. Although our proposed price increases are lower than in the last two years we continue to make the deliberate choice, to ensure that our services maintain service resilience, which matches the Board's low risk appetite for service resilience relative to financial risks.

Strategic Objective(s) this paper relates to: [Click on all that applies]

- ☑ Modernise our operations ☑ Grow and diversify our donor base.